Recent Updates
Recently added Catalysts
CRVS Positive Sentiment Score: 60/100

Corvus Pharmaceuticals to Provide Business Update and Second Quarter 2025 Financial Results on August 7, 2025

Thursday, July 31, 2025 1 min read
Key Takeaway: Corvus Pharmaceuticals has scheduled a conference call and webcast for August 7, 2025, to discuss its business operations and report its second quarter financial results. The event will be accessible via toll-free and international dialing options, and a live webcast is also available. This update is particularly significant as it reflects ongoing developments in the company's clinical-stage biopharmaceutical endeavors, including their lead candidate, soquelitinib.

Market Sentiment Analysis

POSITIVE FACTORS

  • Corvus Pharmaceuticals is actively engaging with investors through an upcoming conference call.
  • The company's innovative approach to cancer treatment could attract interest.
  • The webcast will offer insights into the company's financial health and strategic direction.

Full Press Release Details

SOUTH SAN FRANCISCO, Calif., July 31, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that the company will host a conference call and webcast on August 7, 2025 at 4:30 pm ET (1:30 pm PT) to provide a business update and report second quarter 2025 financial results.
The conference call can be accessed by dialing 1-800-717-1738 (toll-free domestic) or 1-646-307-1865 (international) or by clicking on this link for instant telephone access to the event. The live webcast may be accessed via the investor relations section of the Corvus website.  A replay of the webcast will be available on Corvus’ website for 90 days.
About Corvus Pharmaceuticals
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company pioneering the development of ITK inhibition as a new approach to immunotherapy for a broad range of cancer and immune diseases. The Company’s lead product candidate is soquelitinib, an investigational, oral, small molecule drug that selectively inhibits ITK. Its other clinical-stage candidates are being developed for a variety of cancer indications. For more information, visit www.corvuspharma.com or follow the Company on LinkedIn.
Chief Financial Officer
Corvus Pharmaceuticals, Inc.
llea@corvuspharma.com
sseapy@realchemistry.com

Frequently Asked Questions

When will Corvus Pharmaceuticals host the conference call?

Corvus Pharmaceuticals will host the call on August 7, 2025, at 4:30 pm ET.

How can I access the conference call?

Access the call by dialing 1-800-717-1738 or via the provided online link.

What will be discussed during the conference call?

The call will cover a business update and second quarter 2025 financial results.

Will there be a replay of the conference call?

Yes, a replay of the webcast will be available on the Corvus website for 90 days.

What is soquelitinib used for?

Soquelitinib is an investigational drug aimed at ITK inhibition for cancer treatment.

Tags: CRVS Viatris Investor Conferences Healthcare Corvus Pharmaceuticals biopharmaceutical ITK inhibition cancer treatment soquelitinib
Last updated: Jul 31, 2025